Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
about
Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Systemic therapy for cervical carcinoma - current status.The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.
P2860
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
@ast
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
@en
type
label
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
@ast
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
@en
prefLabel
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
@ast
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
@en
P2860
P356
P1476
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
@en
P2093
Edith Borcoman
P2860
P304
P356
10.1177/1758834017708742
P577
2017-05-08T00:00:00Z